Ihr Broker

  • DAX 0,70
  • EUR/USD 0,50
  • GOLD 0,30

Nur Spreads

Keine Kommission

Jetzt registrieren

CFDs sind komplexe Instrumente und umfassen aufgrund der Hebelfinanzierung ein hohes Risiko, schnell Geld zu verlieren.

PharmaSGP Holding SE, DE000A2P4LJ5

PharmaSGP Holding SE, DE000A2P4LJ5

10.09.2020 - 07:32:58

PharmaSGP with strong revenue and EBIT growth and increased profitability in the first half of 2020

in connection with the preparation of the IPO, increased disproportionately to sales by 17.7% to ? 10.6 million (H1 2019: ? 9.0 million). The adjusted EBIT margin as a percentage of sales thus increased to 31.5% (H1 2019: 28.7%). Unadjusted EBIT amounted to ? 9.5 million, which equates to an EBIT margin of 28.2%.

"We have a clear competitive advantage as a pure-play consumer health company with a clear focus on end consumers, a flexible D2C marketing approach and a very dynamic portfolio development. The positive development of revenue and earnings in the first half of the year confirms once again that we have the right strategy. We will consistently pursue this course in the second half of the year and beyond. We are convinced that with our superior business model, we are very well positioned for the future to be able to exploit the attractive market potential ahead of us," said Natalie Weigand, CEO of PharmaSGP.

In the opinion of the strategy consultants Sempora Consulting, the strengths of the PharmaSGP business model became particularly evident during the market changes caused by the corona pandemic in the first half of 2020. In a performance comparison between close to 50 competitors on how they developed during the first half of the year, PharmaSGP ranked first by far.

In view of the good market positioning, the large number of further product launches planned and, in particular, the imminent launch of the first PharmaSGP drugs in the French market, the Management Board is optimistic. For the full year 2020 the Management Board expects to be able to increase the revenue growth rate of the first half of 2020 as well as to improve the EBIT margin of the first half of the year. These expectations are based on the assumption that there will not be another comprehensive lockdown in the second half of 2020 in connection with the corona pandemic in PharmaSGP's target markets and that product launches proceed as planned.

PharmaSGP will publish the full report for the first half of 2020 on September 30, 2020, at ir.sgp-pharma.com in the "Publications" section.

?

OVERVIEW OF PRELIMINARY H1 FIGURES YEAR-ON-YEAR

Group figures (in ? million) H1 2019 H1 2020 CAGR Revenues 31.6 33.8 7.2% Adjusted EBIT 9.0 10.6 17.7% Unadjusted EBIT 9.0 9.5 5.3% Adjusted EBIT margin 28.7% 31.5% ? Unadjusted EBIT margin 28.7% 28.2% ? ? ? ? ? Revenue by region (in ? million) H1 2019 H1 2020 CAGR Revenue in Germany 23.4 24.6 4.9% Revenue in Italy 3.4 4.1 21.1% Revenue in other European countries 4.7 5.1 8.5% ? ? ? ? Share of revenue by region H1 2019 H1 2020 ? Revenue in Germany 74.2% 72.7% ? Revenue in Italy 10.8% 12.1% ? Revenue in other European countries 15.0% 15.2% ? ? ? ? ? Revenue by product category (in ? million) H1 2019 H1 2020 CAGR Health Brands 23.6 28.6 21.5% Beauty Brands 7.6 5.2 -31.8% ?

CONTACT

cometis AG Claudius Krause Phone: 0611-20585528 Email: ir@sgp-pharma.com

ABOUT PHARMASGP HOLDING SE

PharmaSGP is a pure-play consumer health company with a broad portfolio of leading chemical-free non-prescription pharmaceuticals sold over the counter ("OTC") and other healthcare products. PharmaSGP's products are sold exclusively through pharmacies. Its products are based on natural active pharmaceutical ingredients with documented efficacy and fewer known side effects than most chemical-based pharmaceuticals.

The Company's core brands cover chronic indications, including pain and other age-related ailments. In Germany, PharmaSGP is the market leader for systemic chemical-free pain remedies with its brand families RUBAXX(R) for rheumatic pain and Restaxil(R) for neuralgic pain. Furthermore, PharmaSGP has introduced leading products against sexual weakness and vertigo symptoms.

Since introducing the first product from its current product portfolio in 2012, PharmaSGP has successfully exported its business model to other European countries, including Austria, Italy, France, Belgium and Spain, and it recently obtained marketing authorizations for three of its best-selling products in France.

PharmaSGP generated revenues of ?62.6 million at an EBIT margin of 35.8% in 2019. In order to further expand its competitive position, PharmaSGP plans to increase the number of indications covered by PharmaSGP's product offering, leverage established brand families to introduce new chemical-free OTC and other healthcare products, increase PharmaSGP's European footprint, and accelerate its growth strategy by capitalizing on selected M&A opportunities.

[1] The one-time costs amounted to EUR 1.1 million and include costs such as the setup of organizational and legal structures of the PharmaSGP Group.

10.09.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

Language: English Company: PharmaSGP Holding SE Lochhamer Schlag 21 82166 Gr?felfing

Germany E-mail: ir@sgp-pharma.com Internet: https://sgp-pharma.com ISIN: DE000A2P4LJ5 WKN: A2P4LJ Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich EQS News ID: 1129555 ? End of News DGAP News Service

1129555??10.09.2020?

@ dgap.de